Skip to Content
Merck
CN

SML1938

LY450139

≥98% (HPLC)

Synonym(s):

(2S)-2-Hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide, LY 450139, LY-450139, Semagacestat

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H27N3O4
CAS Number:
425386-60-3
Molecular Weight:
361.44
MDL number:
MFCD09970409
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C([C@@H](NC([C@@H](O)C(C)C)=O)C)N[C@@H](C1=CC=CC=C1CCN2C)C2=O

InChI

1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1

InChI key

PKXWXXPNHIWQHW-RCBQFDQVSA-N

Related Categories

Biochem/physiol Actions

LY450139 (Semagacestat) is a notch-sparing, potent and selective gamma-secretase inhibitor. LY450139 lowers plasma and cerebrospinal fluid Aβ in humans.
Notch-sparing, potent and selective gamma-secretase inhibitor and inverse modulator of Aβ

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
057M4731V
0000016766
0000016767

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Julie Colin et al.
Journal of Alzheimer's disease : JAD, 52(3), 975-987 (2016-05-11)
Oligomeric amyloid-β (Aβ) peptide contributes to impaired synaptic connections and neurodegenerative processes, and as such, represents a primary therapeutic target for Alzheimer's disease (AD)-modifying approaches. However, the lack of efficacy of drugs that inhibit production of Aβ demonstrates the need
Jonathan D Best et al.
The Journal of pharmacology and experimental therapeutics, 313(2), 902-908 (2005-03-04)
The efficacy of gamma-secretase inhibitors in vivo has, to date, been generally assessed in transgenic mouse models expressing increased levels of amyloid-beta (Abeta) peptide thereby allowing the detection of changes in Abeta production. However, it is not clear whether the
Vito Antonio Baldassarro et al.
Disease models & mechanisms, 10(5), 671-678 (2017-02-27)
Microvascular dysfunction is considered an integral part of Alzheimer disease (AD) pathogenesis, but the possible relationship between amyloid pathology, microvascular dysfunction and cell death is still unclear. In order to investigate the influence of intraneuronal amyloid-β (Aβ) accumulation on vulnerability
Peter S B Finnie et al.
Current biology : CB, 30(10), 1934-1940 (2020-04-04)
Memory allows organisms to predict future events based on their prior sampling of the world. Rather than faithfully encoding each detail of related episodes, the brain is thought to incrementally construct probabilistic estimates of environmental statistics that are re-evaluated each

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service